• 검색 결과가 없습니다.

― F-337 ― The investigation of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus in a Korean population

N/A
N/A
Protected

Academic year: 2022

Share "― F-337 ― The investigation of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus in a Korean population"

Copied!
1
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

- S 345 -

― F-337 ―

The investigation of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus in a Korean population

Division of Rheumatology, Department of Internal Medicine, Hanyang University College of Medicine and the Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea1, Department of Genetic Epidemiology, SNP Genetics, Inc.2

*Hee Sun Kim1, Il Kim1, Ji On Kim2, Joon Seol Bae2, Hyoung Doo Shin2, Sang Cheol Bae1

Background & Objective : Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that has a complex genetic trait and cytokines play an important and diverse role in the pathogenesis. It is known that IL-23 is important for the pathogenesis of autoimmune diseases such as experimental autoimmune encephalomyelitis, collagen-induced arthritis, and IBD.

Recently, a Genome-wide association study identified a highly significant association between Crohn's disease and the IL23R gene. The aim of this study was to investigate the association between the interleukin-23 receptor (IL23R) gene polymorphisms and systemic lupus erythematosus (SLE) patients in a Korean population. Methods : We recruited 602 SLE patients and 991 healthy controls from the Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea. Eight SNPs (rs1004819, rs7517847, rs10489629, rs2201841, rs11209026, rs1343151, rs11209032, and rs1495965) were selected for genotyping among previously reported variants. Polymorphic sites were genotyped using amplifying primers and probes designed for TaqMan assay. The genotype distributions of IL23R polymorphisms and haplotypes were compared between the SLE patients and healthy controls with multiple logistic regression models. SLE patients were stratified according to their clinical characteristics based on ACR criteria, autoantibodies and SLICC/ACR damage index, and analyzed their association with each genetic variants. Results : There were no significant differences between SLE patients and healthy controls with any of the IL23R genetic variants in this study.

Similarly, no statistically significant associations were observed between these genetic variants and stratified SLE patients based on the clinico-immunologic features. Conclusions : These results suggest that the polymorphisms located in IL23R gene have no important role in the susceptibility or severity of SLE in the Korean population.

― F-338 ―

Risk factor for osteopenia in young patients with systemic lupus erythematosus

Department of Internal Medicine, Catholic University of Korea., 1Department of Internal Medicine, Sun General Hospital, Daejeon, South Korea

*Hyun-Jin Kim, Bo-Hyoung Park1, Hyun-Sook Kim, Chul-Soo Cho, Wan-Uk Kim

Objective : To study the risk factors for osteopenia in young patients with systemic lupus erythematosus(SLE) and to determine whether osteoclastogenic cytokines, which are known to be elevated in SLE, could affect BMD in SLE. Method : Seventy six patients with SLE and 57 age and gender matched healthy controls were enrolled for this study (mean age; 40.0±5.6 for controls, 37.2±12.1 for SLE). Lumbar and femoral BMD was measured by dual X-ray absorptiometry. Clinical variables evaluated in SLE patients consisted of disease duration, serum complement, anti-dsDNA antibody titer, SLE disease activity index, mean and cumulative dose of steroid, medications including oral calcium, anticoagulant, hydroxychloroquine, azathioprine, cyclosporin, methotrexate and cyclophosphamide, concentrations of serum osteocalcin and urine deoxypyridinoline(DPD), and serum levels of FSH and LH. The levels of several osteoclastogenic cytokines, such as interleukin-6(IL-6), osteoprotegerin (OPG), and soluble receptor activator of NF-kB ligand(sRANKL) were simultaneously measured in the sera of both healthy controls and SLE patients. Results : BMD was decreased in patients with SLE compared to healthy controls(-0.54±1.56 vs -1.22±1.29 g/cm2 at lumbar spine, -0.45±1.10 vs -1.27±1.07 g/cm2 at femur, p=0.05 and p<0.05, respectively). Serum concentration of osteocalcin was also lower in patients with SLE than in healthy controls(6.45±0.52 vs 9.57±0.40 ng/ml, p<0.05), whereas urinary DPD level was higher in SLE patients(67.14±7.06 vs 50.05±4.07, p<0.05). When SLE patients were divided into two groups according to osteopenia, FSH and LH levels were greater in osteopenic SLE patients(n=24) than non-osteopenic patients(n=52)(p=0.03 and p=0.01, respectively). The frequency of menopause also tended to be higher in osteopenic SLE(p=0.053). Conclusion : Elevated FSH and LH levels were the single risk factor linked to osteopenia in SLE. Other factors, including disease activity and osteoclastogenic cytokine levels, did not affect BMD in young SLE. These observations indicate that ovarian dysfunction, which may be associated with SLE itself or cytotoxic agents, is the most important determinant in the progression of osteopenia in young SLE.

참조

관련 문서

The relationship between gene polymorphisms of xenobiotic metabolizing enzymes and colorectal cancer (CRC) incidence has not previously investigated among the Saudi population.

In this study, we firstly identified the genomic structure of the porcine FcRn gene, detected its expression in different tissues and polymorphisms in

The purpose of this study is to investigate the correlation between serum adiponectin level and several parameters, such as interleukin (IL)-6, tumor necrosis factor

Recently, it has been reported that SNPs in the IL-1B gene affect transcription, according to haplotype context, and ge- netic association studies may be

• 대부분의 치료법은 환자의 이명 청력 및 소리의 편안함에 대한 보 고를 토대로

• 이명의 치료에 대한 매커니즘과 디지털 음향 기술에 대한 상업적으로의 급속한 발전으로 인해 치료 옵션은 증가했 지만, 선택 가이드 라인은 거의 없음.. •

12) Maestu I, Gómez-Aldaraví L, Torregrosa MD, Camps C, Llorca C, Bosch C, Gómez J, Giner V, Oltra A, Albert A. Gemcitabine and low dose carboplatin in the treatment of

Key words : Systemic lupus erythematosus, G-CSF, Bronchoalveolar lavage, Acute promyelo- cytic leukemia... 수술 후 DIC, 패혈증을 의심하여 항생제 치료를 시작하였고